查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947970

按产品类型、分子类型、分销管道、最终用户和给药方法分類的肠外暴露前预防（PrEP）市场，全球预测，2026-2032年

Parenteral PrEP Market by Product Type, Molecule Type, Distribution Channel, End Users, Regimen - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 187 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，注射用 PrEP 市场价值将达到 4.3556 亿美元，到 2026 年将成长至 4.9036 亿美元，到 2032 年将达到 10.3853 亿美元，复合年增长率为 13.21%。

关键市场统计数据
基准年 2025 4.3556亿美元
预计年份：2026年 4.9036亿美元
预测年份 2032 1,038,530,000 美元
复合年增长率 (%) 13.21%

这是一份简洁且权威的介绍，概述了影响肠外暴露前预防（PrEP）领域的临床进展、管理创新和决策者优先事项。

注射用PrEP代表了HIV预防领域的模式转移，它引入了一种长效给药方式，减轻了患者的用药负担，并为不同高危险群提供了更多选择。本执行摘要总结了近期临床进展、不断发展的给药模式、支付方的考量以及供应链趋势，旨在为决策者制定策略提供简明扼要的依据。其目标是将复杂的临床和商业性进展转化为製造商、医疗系统和专案设计者可操作的方向。

清楚阐述长效药物、植入式技术和分散式交付模式如何重塑预防策略和服务模式。

肠外暴露前预防（PrEP）领域正经历变革性的转变，这主要得益于技术创新、以病人为中心的服务模式以及支付方的调整。长效药物和植入式系统正在重新定义预防，它们延长了保护期，改变了用药依从性，并催生了医疗服务中新的接触点策略。随着产品特性的演变，人们对监测、诊所工作流程以及在医疗服务过渡期间维持保护连续性的机制的期望也在不断变化。

对 2025 年美国关税如何迫使製造商和供应链领导者重塑其采购、物流和采购策略进行实际分析。

2025年美国关税的实施进一步增加了注射用PrEP产品全球采购和分销计划的复杂性。製造商和经销商被迫重新评估其筹资策略、供应链路线和成本会计框架，以在确保利润率的同时，维持在不同支付方环境下的产品供应。关税影响了本地生产、组件采购以及与物流供应商的合约条款等方面的考量，也为更深入评估各国层级的商业风险提供了契机。

基于深度细分的洞察，将产品结构、分子特征、分销模式、终端用户能力和给药方案与策略决策联繫起来

按产品、分子、分销管道、最终用户和给药方案进行细分，揭示了肠外暴露前预防（PrEP）生态系统中存在的差异化影响。按产品类型划分，植入式装置在监管和生命週期管理方面具有独特的考量，而可生物降解聚合物与不可生物降解聚合物相比，在患者便利性和药物清除特性方面存在显着差异。对于长效注射剂，分子特异性的临床和给药特性至关重要。卡博特韦和来那卡帕韦各自有特定的给药持续时间、监测需求和病人咨询需求。预填充式注射器在某些临床环境中操作便捷，但需要仔细考虑低温运输管理和处置方法。

从全面的区域观点分析不同监管、支付和医疗服务系统如何影响关键区域的采纳和准入动态。

区域动态对美洲、欧洲、中东和非洲以及亚太地区的临床应用路径、支付方接受度和分销物流有显着影响。在美洲，创新治疗方法的引入往往透过整合医疗体系和社区计画来实现，这些体系和计画优先考虑公平获取推广，并有针对性地涵盖高风险族群。该地区公私支付方并存的格局，既为报销谈判带来了机会，也带来了复杂性，因此更需要建立病患支援机制，以协助病患启动治疗。

公司层面的策略重点在于整合商业化、与支付方合作以及提高生产柔软性，以推动长效预防解决方案的发展。

注射用PrEP领域的主要企业正在调整其商业化策略和临床开发计划，以适应长效植入式技术的特性。策略重点包括建立健全的上市后安全性监测系统，开发病患支援计画以协助治疗的启动和维持，以及投资提升生产柔软性以适应多种剂型。药物研发人员、医疗设备製造商和专业经销商之间的合作正变得至关重要，这有助于创建整合解决方案，从而简化临床工作流程并提高患者依从性。

针对製造商、支付者和医疗服务提供者的实用建议：使证据产生、分发设计和风险缓解与传播目标保持一致

为了最大限度地发挥肠外暴露前预防（PrEP）的社会和商业性价值，产业领导者应采取多方相关人员的方式，协调临床开发、报销策略和分散式服务。首先，将支付方的证据要求纳入后期临床项目，将减少后续环节的摩擦，并加快医保覆盖范围的讨论。其次，投资于患者支援基础设施，例如数位化药物管理工具、宅配物流和咨询资源，将有助于在不同的医疗环境中启动和维持治疗。第三，企业和采购方应优化其生产和筹资策略，透过地理多元化和策略伙伴关係来降低贸易政策和关税风险。

对用于得出对相关人员具有实际意义的见解的证据综合、专家参与和分析方法进行透明的解释

本研究整合了已发表的临床文献、监管指导文件、同行评审研究以及对临床、支付者和供应链专家的访谈，旨在全面了解肠外给药的暴露前预防（PrEP）生态系统。资料收集优先考虑近期临床试验结果、同行评审的安全分析以及能够揭示实际应用挑战的实施研究。专家咨询旨在了解医院、社区诊所、专科诊所和分销合作伙伴的运作实际情况，从而提供关于推广应用障碍和促进因素的实证观点。

综合结论概述了整合临床创新、分销韧性和相关人员合作以推进预防工作的策略要务。

长效注射剂和植入式装置的融合、不断演变的分销模式以及复杂的支付环境，共同促成了肠外暴露前预防（PrEP）应用的一个关键时刻。决策者必须仔细考虑产品的特定临床考量、通路选择和区域监管环境，同时也要因应贸易政策变化所带来的供应链风险增加。然而，协调临床、营运和商业性策略，将为扩大PrEP的可及性、减轻用药负担以及为高风险族群提供多样化的预防选择带来巨大潜力。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 依产品类型分類的肠外暴露前预防市场

  • 植入式医疗器材
    • 可生物降解聚合物
    • 不可生物降解聚合物
  • 长效注射剂
    • 卡博特格拉维尔
    • 莉娜·卡帕大厦
  • 预填充式注射器

9. 依分子类型分類的肠外暴露前预防市场

  • 卡博特格拉维尔
  • 莉娜·卡帕大厦

10. 按分销管道分類的肠外PrEP市场

  • 直接面向患者的计划
    • 宅配服务
    • 邮购
  • 医院药房
  • 零售药房
  • 专科诊所
    • 社区医疗中心
    • 感染疾病诊所

11. 依最终使用者分類的肠外暴露前预防市场

  • 社区医疗中心
    • 地区
    • 都市区
  • 爱滋病诊所
  • 研究中心
    • 学术机构
    • 私人研究机构

12. 依给药途径分類的肠外暴露前预防市场

  • 随选管理
  • 常规管理

13. 按地区分類的肠外暴露前预防市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

14. 按组别分類的肠外暴露前预防市场

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

15. 各国肠外暴露前预防市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

16. 美国肠外暴露前预防市场

17. 中国：注射用PrEP市场

第十八章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Accord Healthcare Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Fresenius Kabi AG
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan NV
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Viatris Inc.
  • ViiV Healthcare Limited
Product Code: MRR-4F7A6D4FB6B4

The Parenteral PrEP Market was valued at USD 435.56 million in 2025 and is projected to grow to USD 490.36 million in 2026, with a CAGR of 13.21%, reaching USD 1,038.53 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 435.56 million
Estimated Year [2026] USD 490.36 million
Forecast Year [2032] USD 1,038.53 million
CAGR (%) 13.21%

Concise and authoritative introduction framing clinical progress, delivery innovation, and decision-maker priorities shaping the parenteral PrEP landscape

Parenteral pre-exposure prophylaxis (PrEP) represents a paradigm shift in HIV prevention, introducing long-acting modalities that reduce adherence burdens and expand choices for diverse populations at risk. This executive summary synthesizes recent clinical advances, evolving delivery models, payer considerations, and supply chain dynamics to offer decision-makers a concise foundation for strategy development. The aim is to translate complex clinical and commercial developments into actionable direction for manufacturers, health systems, and program designers.

Over the past several years, injectable and implantable platforms have matured from investigational concepts to clinically validated alternatives to daily oral regimens. As a result, stakeholders face new questions about patient selection, service delivery networks, and integration with existing prevention infrastructures. This section sets the stage for deeper analysis, emphasizing the intersection of scientific progress with pragmatic implementation considerations and highlighting how evidence, regulation, and patient preference collectively shape uptake trajectories.

Clear articulation of how long-acting agents, implantable technologies, and decentralized delivery paradigms are reshaping prevention strategies and service models

The landscape for parenteral PrEP is undergoing transformative shifts driven by technological innovation, patient-centered delivery models, and payer adaptation. Long-acting agents and implantable systems are redefining prophylaxis by extending protection windows, thereby altering adherence dynamics and enabling novel touchpoint strategies within healthcare delivery. As product profiles evolve, so too do expectations for monitoring, clinic workflows, and mechanisms to maintain continuity of protection during care transitions.

Concurrently, distribution channels are diversifying to accommodate decentralized care, with direct-to-patient programs and specialty clinic partnerships becoming central to reach underserved populations. Regulatory clarity around long-acting formulations and implantable devices is improving, prompting manufacturers to prioritize lifecycle planning and post-market surveillance. Taken together, these shifts necessitate integrated commercial strategies that align clinical value propositions with operational realities and sustainable reimbursement pathways.

Practical analysis of how US tariff measures enacted in 2025 have compelled manufacturers and supply chain leaders to reconfigure sourcing, logistics, and procurement tactics

The introduction of tariffs in the United States in 2025 has layered additional complexity onto global procurement and distribution planning for parenteral PrEP products. Manufacturers and distributors have had to reassess sourcing strategies, supply chain routing, and costing frameworks to preserve margins while maintaining access across varied payer landscapes. The tariffs influence considerations around local manufacturing, component sourcing, and contractual terms with logistics providers, prompting a more granular evaluation of country-level operational risk.

In response, supply chain teams are prioritizing resilience through diversified supplier networks, nearshoring of critical components, and contractual hedges that mitigate the impact of trade policy volatility. Health systems and procurement entities are likewise examining procurement windows and inventory policies to buffer short-term cost fluctuations. Ultimately, the tariff environment has underscored the importance of flexible manufacturing strategies and collaborative contracting as prerequisites for sustaining dependable access to long-acting prevention modalities.

Deep segmentation-driven insights connecting product architectures, molecule attributes, distribution models, end-user capacities, and dosing regimens to strategic decisions

Insights drawn from product, molecule, distribution channel, end-user, and regimen segmentation reveal differentiated implications across the parenteral PrEP ecosystem. When viewed by product type, implantable devices present unique device-regulatory and lifecycle management considerations, with biodegradable polymers offering distinct patient convenience and removal profiles compared with non-biodegradable polymers. Long-acting injectables foreground molecule-specific clinical and dosing characteristics, where cabotegravir and lenacapavir each carry particular administration windows, monitoring expectations, and patient counseling requirements. Prefilled syringes add operational simplicity for some clinical settings but require attention to cold chain and disposal practices.

Examining segmentation by molecule type highlights how cabotegravir and lenacapavir demand bespoke clinical pathways, pharmacovigilance programs, and education initiatives to ensure appropriate patient selection. Distribution channel segmentation indicates that direct-to-patient programs, including home delivery and mail order, can expand reach and convenience, while hospital and retail pharmacies remain pivotal for integration with broader care services. Specialty clinics, comprising community health centers and infectious disease clinics, serve as critical hubs for initiation and follow-up. End-user segmentation underscores differing operational environments: community health centers, both rural and urban, must balance resource constraints and local outreach; HIV clinics focus on clinical continuity and complex case management; research centers, spanning academic institutions and private research organizations, continue to inform best practices. Finally, regimen segmentation separates on-demand dosing, including post-exposure-only and pre-exposure-only approaches, from periodic dosing schedules such as two-month and three-month intervals, each of which shapes adherence support, visit cadence, and refill logistics. Integrating these segmentation perspectives enables stakeholders to tailor product development, distribution strategies, and patient engagement to the nuanced needs of target populations and delivery environments.

Comprehensive regional perspective on how differing regulatory, payer, and delivery ecosystems across major geographies influence rollout and access dynamics

Regional dynamics exert a powerful influence on clinical adoption pathways, payer receptivity, and distribution logistics across the Americas, Europe Middle East & Africa, and Asia-Pacific. In the Americas, innovation adoption tends to be channeled through integrated health systems and community-based programs that prioritize equitable access and targeted outreach to populations with elevated risk profiles. The combination of private and public payers in this region creates both opportunities and complexity for reimbursement negotiations and further necessitates patient assistance mechanisms to support initiation.

In Europe, Middle East & Africa, regulatory heterogeneity and variable infrastructure necessitate adaptable deployment models, with some markets favoring centralized procurement and others relying on local programmatic delivery. Regional philanthropic initiatives and multilateral partnerships continue to play a role in accelerating access in resource-constrained settings. Moving to Asia-Pacific, diverse regulatory pathways and manufacturing capacity present opportunities for regional production partnerships and technology transfer, while varying healthcare delivery models drive differentiated uptake patterns. Across all regions, tailored engagement with payers, policymakers, and community stakeholders remains essential to align commercial plans with public health objectives and to ensure that innovations translate into sustained access.

Strategic company-level priorities emphasizing integrated commercialization, payer engagement, and manufacturing flexibility to advance long-acting prevention solutions

Leading companies active in the parenteral PrEP space are aligning clinical development plans with commercialization tactics that reflect the unique characteristics of long-acting agents and implantable technologies. Strategic priorities include establishing robust post-market safety surveillance, developing patient support programs that address initiation and continuation, and investing in manufacturing flexibility to support multiple delivery formats. Partnerships between pharmaceutical developers, device manufacturers, and specialty distributors are becoming central to creating integrated offerings that streamline clinic workflows and support patient adherence.

Corporate strategies also emphasize payer engagement early in development to clarify evidence needs for coverage determinations, and to design value demonstrations that quantify health system benefits beyond simple clinical endpoints. In parallel, companies are exploring differentiated service models-such as bundled service agreements for clinics or subscription-based supply arrangements-to reduce friction in adoption. Collectively, these initiatives reflect a shift from product-only commercialization toward solutions that blend clinical efficacy, operational simplicity, and payer-aligned value propositions.

Action-oriented recommendations for manufacturers, payers, and providers to align evidence generation, distribution design, and risk mitigation with adoption goals

Industry leaders should adopt a multi-stakeholder approach that synchronizes clinical development, reimbursement strategy, and decentralized delivery to maximize the societal and commercial value of parenteral PrEP. First, embedding payer evidence requirements into late-stage clinical programs will reduce downstream friction and accelerate coverage conversations. Second, investing in patient support infrastructure-digital adherence tools, home delivery logistics, and counseling resources-will ease initiation and retention across diverse care settings. Third, companies and purchasers should closely examine manufacturing and sourcing strategies to mitigate trade policy and tariff risks through geographic diversification and strategic partnerships.

Operationally, aligning distribution strategies with the capacities of hospitals, specialty clinics, and community health centers will be critical; direct-to-patient programs should be piloted alongside traditional channels to evaluate real-world adherence and patient satisfaction. In addition, collaborative pilots with public health authorities can validate integration pathways and build evidence for broader adoption. Executing these recommendations will require cross-functional coordination, near-term investments in infrastructure, and ongoing engagement with community stakeholders to ensure equitable access and sustained uptake.

Transparent explanation of the evidence synthesis, expert engagement, and analytic approaches used to derive pragmatic insights for stakeholders

This research synthesizes publicly available clinical literature, regulatory guidance documents, peer-reviewed studies, and primary interviews with clinical, payer, and supply chain experts to construct a holistic view of the parenteral PrEP ecosystem. Data collection prioritized recent clinical trial results, peer-reviewed safety analyses, and implementation studies that illuminate real-world delivery challenges. Expert consultations were structured to capture operational realities across hospitals, community clinics, specialty providers, and distribution partners, providing grounded perspectives on adoption barriers and enablers.

Analytic methods combined qualitative thematic synthesis with scenario-based operational assessment to identify strategic inflection points for stakeholders. Where applicable, findings were triangulated across multiple evidence streams to enhance robustness. The methodology emphasizes transparency in data sourcing and acknowledges limitations where evidence remains emergent, particularly for novel implantable technologies and long-term safety profiles, while prioritizing actionable implications for commercial and public health decision-making.

Integrated conclusion summarizing strategic imperatives for aligning clinical innovation, distribution resilience, and stakeholder collaboration to advance prevention

The convergence of long-acting injectables and implantable devices, evolving distribution models, and complex payer environments creates a pivotal moment for parenteral PrEP implementation. Decision-makers must navigate product-specific clinical considerations, distribution channel choices, and regional regulatory landscapes while managing supply chain risks heightened by trade policy shifts. Nevertheless, the potential to expand access, reduce adherence burden, and diversify prevention options for at-risk populations is substantial when strategies are aligned across clinical, operational, and commercial dimensions.

Moving forward, sustained collaboration among developers, health systems, payers, and community organizations will be essential to translate technical advances into durable public health impact. By focusing on evidence generation that resonates with payers, investing in flexible supply chain and distribution solutions, and centering patient experience in delivery design, stakeholders can accelerate responsible adoption and ensure long-acting prophylaxis becomes an accessible option for those who will benefit most.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Parenteral PrEP Market, by Product Type

  • 8.1. Implantable Device
    • 8.1.1. Biodegradable Polymers
    • 8.1.2. Non-Biodegradable Polymers
  • 8.2. Long-Acting Injectable
    • 8.2.1. Cabotegravir
    • 8.2.2. Lenacapavir
  • 8.3. Prefilled Syringes

9. Parenteral PrEP Market, by Molecule Type

  • 9.1. Cabotegravir
  • 9.2. Lenacapavir

10. Parenteral PrEP Market, by Distribution Channel

  • 10.1. Direct-To-Patient Programs
    • 10.1.1. Home Delivery
    • 10.1.2. Mail Order
  • 10.2. Hospital Pharmacies
  • 10.3. Retail Pharmacies
  • 10.4. Specialty Clinics
    • 10.4.1. Community Health Centers
    • 10.4.2. Infectious Disease Clinics

11. Parenteral PrEP Market, by End Users

  • 11.1. Community Health Centers
    • 11.1.1. Rural Centers
    • 11.1.2. Urban Centers
  • 11.2. HIV Clinics
  • 11.3. Research Centers
    • 11.3.1. Academic Institutions
    • 11.3.2. Private Research Organizations

12. Parenteral PrEP Market, by Regimen

  • 12.1. On-Demand Dosing
  • 12.2. Periodic Dosing

13. Parenteral PrEP Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Parenteral PrEP Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Parenteral PrEP Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Parenteral PrEP Market

17. China Parenteral PrEP Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Accord Healthcare Inc.
  • 18.6. Amneal Pharmaceuticals, Inc.
  • 18.7. Aurobindo Pharma Ltd.
  • 18.8. Cipla Ltd.
  • 18.9. Dr. Reddy's Laboratories Ltd.
  • 18.10. Fresenius Kabi AG
  • 18.11. Gilead Sciences, Inc.
  • 18.12. Hetero Labs Limited
  • 18.13. Lupin Limited
  • 18.14. Merck & Co., Inc.
  • 18.15. Mylan N.V.
  • 18.16. Sun Pharmaceutical Industries Ltd.
  • 18.17. Teva Pharmaceutical Industries Ltd.
  • 18.18. Viatris Inc.
  • 18.19. ViiV Healthcare Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL PARENTERAL PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL PARENTERAL PREP MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL PARENTERAL PREP MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL PARENTERAL PREP MARKET SIZE, BY END USERS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL PARENTERAL PREP MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL PARENTERAL PREP MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES PARENTERAL PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA PARENTERAL PREP MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL PARENTERAL PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL PARENTERAL PREP MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL PARENTERAL PREP MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL PARENTERAL PREP MARKET SIZE, BY BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL PARENTERAL PREP MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL PARENTERAL PREP MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL PARENTERAL PREP MARKET SIZE, BY NON-BIODEGRADABLE POLYMERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL PARENTERAL PREP MARKET SIZE, BY CABOTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL PARENTERAL PREP MARKET SIZE, BY CABOTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL PARENTERAL PREP MARKET SIZE, BY CABOTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL PARENTERAL PREP MARKET SIZE, BY LENACAPAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL PARENTERAL PREP MARKET SIZE, BY LENACAPAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL PARENTERAL PREP MARKET SIZE, BY LENACAPAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL PARENTERAL PREP MARKET SIZE, BY PREFILLED SYRINGES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL PARENTERAL PREP MARKET SIZE, BY PREFILLED SYRINGES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL PARENTERAL PREP MARKET SIZE, BY PREFILLED SYRINGES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL PARENTERAL PREP MARKET SIZE, BY CABOTEGRAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL PARENTERAL PREP MARKET SIZE, BY CABOTEGRAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL PARENTERAL PREP MARKET SIZE, BY CABOTEGRAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL PARENTERAL PREP MARKET SIZE, BY LENACAPAVIR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL PARENTERAL PREP MARKET SIZE, BY LENACAPAVIR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL PARENTERAL PREP MARKET SIZE, BY LENACAPAVIR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL PARENTERAL PREP MARKET SIZE, BY HOME DELIVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL PARENTERAL PREP MARKET SIZE, BY HOME DELIVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL PARENTERAL PREP MARKET SIZE, BY HOME DELIVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL PARENTERAL PREP MARKET SIZE, BY MAIL ORDER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL PARENTERAL PREP MARKET SIZE, BY MAIL ORDER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL PARENTERAL PREP MARKET SIZE, BY MAIL ORDER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL PARENTERAL PREP MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL PARENTERAL PREP MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL PARENTERAL PREP MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL PARENTERAL PREP MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL PARENTERAL PREP MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL PARENTERAL PREP MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL PARENTERAL PREP MARKET SIZE, BY INFECTIOUS DISEASE CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL PARENTERAL PREP MARKET SIZE, BY INFECTIOUS DISEASE CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL PARENTERAL PREP MARKET SIZE, BY INFECTIOUS DISEASE CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PARENTERAL PREP MARKET SIZE, BY RURAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PARENTERAL PREP MARKET SIZE, BY RURAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL PARENTERAL PREP MARKET SIZE, BY RURAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL PARENTERAL PREP MARKET SIZE, BY URBAN CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL PARENTERAL PREP MARKET SIZE, BY URBAN CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL PARENTERAL PREP MARKET SIZE, BY URBAN CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL PARENTERAL PREP MARKET SIZE, BY HIV CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL PARENTERAL PREP MARKET SIZE, BY HIV CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL PARENTERAL PREP MARKET SIZE, BY HIV CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL PARENTERAL PREP MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL PARENTERAL PREP MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL PARENTERAL PREP MARKET SIZE, BY ACADEMIC INSTITUTIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL PARENTERAL PREP MARKET SIZE, BY PRIVATE RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL PARENTERAL PREP MARKET SIZE, BY PRIVATE RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL PARENTERAL PREP MARKET SIZE, BY PRIVATE RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL PARENTERAL PREP MARKET SIZE, BY ON-DEMAND DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL PARENTERAL PREP MARKET SIZE, BY ON-DEMAND DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL PARENTERAL PREP MARKET SIZE, BY ON-DEMAND DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL PARENTERAL PREP MARKET SIZE, BY PERIODIC DOSING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL PARENTERAL PREP MARKET SIZE, BY PERIODIC DOSING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL PARENTERAL PREP MARKET SIZE, BY PERIODIC DOSING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL PARENTERAL PREP MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS PARENTERAL PREP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AMERICAS PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 98. AMERICAS PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 99. AMERICAS PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 100. AMERICAS PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 101. AMERICAS PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 102. AMERICAS PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 103. AMERICAS PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 107. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 108. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 117. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 127. LATIN AMERICA PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 137. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 138. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 139. EUROPE, MIDDLE EAST & AFRICA PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 140. EUROPE PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 141. EUROPE PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. EUROPE PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 143. EUROPE PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 144. EUROPE PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. EUROPE PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. EUROPE PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 147. EUROPE PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 148. EUROPE PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 149. EUROPE PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 150. EUROPE PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 151. EUROPE PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 152. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 153. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 154. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 155. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 156. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 157. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 158. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 159. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 160. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 161. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 162. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 163. MIDDLE EAST PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 164. AFRICA PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 165. AFRICA PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 166. AFRICA PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 167. AFRICA PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 168. AFRICA PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. AFRICA PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 170. AFRICA PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 171. AFRICA PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 172. AFRICA PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 173. AFRICA PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 174. AFRICA PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 175. AFRICA PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 176. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 177. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 178. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 179. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 180. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 182. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 183. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 184. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 185. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 186. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 187. ASIA-PACIFIC PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 188. GLOBAL PARENTERAL PREP MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 191. ASEAN PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 192. ASEAN PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 193. ASEAN PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. ASEAN PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 195. ASEAN PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 196. ASEAN PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 197. ASEAN PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 198. ASEAN PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 199. ASEAN PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 200. ASEAN PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 201. GCC PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 202. GCC PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. GCC PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 204. GCC PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 205. GCC PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. GCC PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. GCC PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 208. GCC PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 209. GCC PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 210. GCC PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 211. GCC PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 212. GCC PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 221. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 222. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 223. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 224. EUROPEAN UNION PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 225. BRICS PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 226. BRICS PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 227. BRICS PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 228. BRICS PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 229. BRICS PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 230. BRICS PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 231. BRICS PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 232. BRICS PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 233. BRICS PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 234. BRICS PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 235. BRICS PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 236. BRICS PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 237. G7 PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. G7 PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 239. G7 PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 240. G7 PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 241. G7 PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 242. G7 PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 243. G7 PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 244. G7 PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 245. G7 PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 246. G7 PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 247. G7 PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 248. G7 PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 249. NATO PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 250. NATO PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 251. NATO PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 252. NATO PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 253. NATO PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 254. NATO PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 255. NATO PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 256. NATO PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 257. NATO PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 258. NATO PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 259. NATO PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 260. NATO PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 261. GLOBAL PARENTERAL PREP MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 262. UNITED STATES PARENTERAL PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 263. UNITED STATES PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 264. UNITED STATES PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 265. UNITED STATES PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 266. UNITED STATES PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. UNITED STATES PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 268. UNITED STATES PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 269. UNITED STATES PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 270. UNITED STATES PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 271. UNITED STATES PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 272. UNITED STATES PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 273. UNITED STATES PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 274. CHINA PARENTERAL PREP MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 275. CHINA PARENTERAL PREP MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. CHINA PARENTERAL PREP MARKET SIZE, BY IMPLANTABLE DEVICE, 2018-2032 (USD MILLION)
  • TABLE 277. CHINA PARENTERAL PREP MARKET SIZE, BY LONG-ACTING INJECTABLE, 2018-2032 (USD MILLION)
  • TABLE 278. CHINA PARENTERAL PREP MARKET SIZE, BY MOLECULE TYPE, 2018-2032 (USD MILLION)
  • TABLE 279. CHINA PARENTERAL PREP MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 280. CHINA PARENTERAL PREP MARKET SIZE, BY DIRECT-TO-PATIENT PROGRAMS, 2018-2032 (USD MILLION)
  • TABLE 281. CHINA PARENTERAL PREP MARKET SIZE, BY SPECIALTY CLINICS, 2018-2032 (USD MILLION)
  • TABLE 282. CHINA PARENTERAL PREP MARKET SIZE, BY END USERS, 2018-2032 (USD MILLION)
  • TABLE 283. CHINA PARENTERAL PREP MARKET SIZE, BY COMMUNITY HEALTH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 284. CHINA PARENTERAL PREP MARKET SIZE, BY RESEARCH CENTERS, 2018-2032 (USD MILLION)
  • TABLE 285. CHINA PARENTERAL PREP MARKET SIZE, BY REGIMEN, 2018-2032 (USD MILLION)